BLACKROCK IS CASHING IN ON CHILDREN: $771 MILLION PROFIT FROM GENDER TRANSITIONS
Truth seekers, the time is now! Join our Telegram Channel and be part of the journey for real stories!
BlackRock is making $771 million from investments in gender transition drugs for minors through Eli Lilly. This isn’t care—it’s a ruthless profit scheme hiding behind identity politics.
This isn’t a conspiracy theory. This is cold, hard financial reality.
Wall Street has found its next goldmine, and it’s not oil. It’s children.
America is staring into a mirror, and what it sees should rattle every parent to the core. Behind the rhetoric, the activism, the rainbow flags, and the “care” lies a beast we’ve seen before: profit—raw, ruthless, and unrelenting. And at the center of it is BlackRock.
Let me say it loud: Transitioning minors has become a billion-dollar industry, and BlackRock, the largest asset manager on Earth, is riding the wave all the way to the bank.
Behind the Smokescreen: What’s Really Going On
Most Americans hear “gender-affirming care” and think it’s a private, personal decision. They imagine thoughtful counseling, compassionate doctors, and a journey guided by science and love.
That’s the marketing.
Here’s the reality: gender medicine is now a business model. A repeat-customer, pharmaceutical-dependent, irreversible-treatment cash cow.
And who’s helping fuel it? BlackRock, through its investment in Eli Lilly, a pharmaceutical titan with deep stakes in the transgender medical space.
Yes, Eli Lilly—the insulin giant—has diversified. They’re not just selling meds. They’re selling lifelong medical dependency under the banner of identity.
$771 Million in Blood Money
Let that number sit for a second: $771 million.
That’s how much BlackRock has profited from its stake in Eli Lilly, a company entrenched in the gender pharmaceutical pipeline.
Puberty blockers, synthetic hormones, and follow-up treatments that stretch across decades—Eli Lilly plays a key role in supplying the drugs that fuel it all.
What used to be niche has become mainstream. And BlackRock saw it coming. Early. They moved fast. They placed their bets. Now they’re collecting.
Is this care—or is this commerce?
Children Are Not Markets
Let’s call this what it is: a moral crime masquerading as progress.
We’re no longer talking about consenting adults. We’re talking about children—vulnerable, confused, often struggling with anxiety, trauma, and depression—being fast-tracked into irreversible medicalization.
We’re talking about 13-year-olds being injected with hormones that shut down their development and permanently alter their bodies.
And behind all of it? Pharma. Wall Street. BlackRock.
These are not healers. They are investors. And their job is to maximize return. They don’t care about kids. They care about quarterly earnings.
The Pipeline of Profit
It starts with “care.”
A child sees a counselor. The counselor refers them to a gender clinic. The clinic prescribes puberty blockers. Then cross-sex hormones. Then surgeries. Then more hormones. Forever.
Each step of the process is billable. Each dose is a product. Each patient is a revenue stream.
This is not a one-time procedure. It’s not like getting your tonsils out. This is a lifelong commitment to pharmaceuticals.
And Eli Lilly is one of the key players. Their name doesn’t appear in the headlines, but it should. They profit every time a prescription is written. And BlackRock profits every time Eli Lilly stock goes up.
“Affirmation” as a Business Model
Let’s rip the mask off: “affirmation” isn’t a philosophy. It’s a sales tactic.
It eliminates friction. No questioning. No second opinions. No alternatives.
Just nod, prescribe, profit.
The fewer questions asked, the faster the drugs get sold.
The ideology is the cover. The profit is the motive.
Wall Street Has No Soul
If you still think Wall Street draws ethical lines, you haven’t been paying attention.
These are the same institutions that fueled the opioid crisis.
The same ones that bet against the housing market and evicted millions.
Now they’ve found a new frontier—gender medicine.
And they don’t care if it destroys families, sterilizes teens, or rewrites childhood.
They care if it’s scalable.
The Money Trail Is Real
Let’s break this down clearly.
Eli Lilly manufactures hormone therapy drugs, including estrogen and testosterone formulations used in gender transitions.
These drugs are prescribed increasingly to minors, sometimes as young as 12, often without full parental consent.
BlackRock owns massive equity in Eli Lilly and holds their stock in portfolios that millions of Americans don’t even realize they’re part of.
BlackRock made $771 million on these holdings as gender medicine exploded in visibility and volume.
This is no longer about compassion.
It’s about cash flow.
What Happens When the Market Changes?
Here’s the most chilling part: Wall Street doesn’t bet on what’s right. It bets on what grows.
What happens when de-transitioners start suing?
When whistleblowers emerge?
When families speak out about irreversible harm?
Will BlackRock back off?
Will Eli Lilly apologize?
Of course not. They’ll pivot. They’ll rebrand.
They’ll sell the next thing.
And the kids left behind? Just collateral.
We Must Wake Up
As an American, a citizen, I say this with urgency and anger:
We are letting our children be monetized.
This is not healthcare. This is not love. This is not justice.
This is the commodification of identity.
The financialization of childhood.
The corporate takeover of the most intimate, vulnerable years of human life.
You Are Funding This—Whether You Know It or Not
Do you have a 401(k)? A retirement account? An ETF?
Check it. You might be invested in BlackRock.
Which means: you might be making money off of gender transitions, too.
It’s time to look hard at the machine we’ve built.
Because while we were arguing about bathrooms and pronouns, Wall Street turned ideology into enterprise.
And now? They’re cashing in—big time.
Final Words: The Line Has Been Crossed
There’s no middle ground left here.
This is a fight for truth, for children, for the future of medicine, and for the soul of this country.
BlackRock doesn’t care who gets hurt—as long as the numbers rise.
They see children’s bodies as market opportunities.
And unless we speak up, push back, and name it for what it is, they will keep profiting.
Enough is enough.
We are not lab rats.
Our children are not investments.
This is America, not an open-air testing site for billionaires.
We need accountability.
We need transparency.
And most of all—we need courage.
Start asking. Start looking. Start shouting. Before another kid becomes a line on a ledger.
BlackRock owns a healthcare company called Eli Lilly
This company specializes in gender affirming care for minors
BlackRock has profited $771 million dollars from holding this stock
Transitioning children is making BlackRock a fortune
SGTnewsNetwork pic.twitter.com/eyEqw6f3di
— Jack Straw (@JackStr42679640) April 3, 2025
Our mission to champion democracy, freedom of speech, and patriotic values relies on the support of dedicated individuals like you. Your contribution is vital in helping us provide insightful analysis, uncover pressing issues, and inspire positive change in our nation.
Join us in our commitment to making a difference. Every donation counts and empowers us to continue our work in advocating for the values we hold dear.
Thank you for being a crucial part of our journey.
I’m a 33-year-old writer and the founder of World Reports Today. Driven by the timeless principles of democracy and freedom of speech, I use my platform and my writing to amplify the voices of those who uphold these ideals and to spark meaningful conversations about the issues that truly matter.
